Allergan PLC (AGN)

192.21
3.70 2.00
NYSE : Health Care
Prev Close 188.47
Open 189.31
Day Low/High 189.13 / 196.30
52 Wk Low/High 184.50 / 317.48
Volume 3.00M
Avg Volume 4.84M
Exchange NYSE
Shares Outstanding 374.95M
Market Cap 71.14B
EPS 10.00
P/E Ratio 13.89
Div & Yield 2.80 (1.50%)

Latest News

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Allergan Plc To Contact The Firm

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Allergan Plc To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

Pullbacks Are Getting Shorter

Breadth is good (not great), but sentiment is a concern.

Cramer: With Trump, Everything's a Negotiation

Cramer: With Trump, Everything's a Negotiation

Just ask the drug companies or Boeing.

Allergan Moves Up In Analyst Rankings, Passing General Growth Properties

Allergan Moves Up In Analyst Rankings, Passing General Growth Properties

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Allergan PLC has taken over the #85 spot from General Growth Properties Inc , according to ETF Channel. Below is a chart of Allergan PLC versus General Growth Properties Inc plotting their respective rank within the S&P 500 over time (AGN plotted in blue; GGP plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

Keeping an Eye on Oil and Allergan

Caution ahead of OPEC meeting; drugmaker still hindered.

Cramer: Trump Tells Boeing, 'This Won't Fly'

Cramer: Trump Tells Boeing, 'This Won't Fly'

Tweet on Air Force One cost overruns is ominous for companies dependent on government.

Questions Mount at Teva as Generics Head Quits Without Explanation

Questions Mount at Teva as Generics Head Quits Without Explanation

Siggi Olfasson is poised to step down as president and CEO of Teva's global generic medicines group by the end the first quarter of 2017.

Cramer: We Are in Stage 2 of the Trump Love Affair With Business

Cramer: We Are in Stage 2 of the Trump Love Affair With Business

Hillary isn't the only one who seems to favor workers over capital. Trump does, too.

Apple, Starbucks, Cisco: Doug Kass' Views

Apple, Starbucks, Cisco: Doug Kass' Views

Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'

Weekly Roundup

OPEC deal is among the highlights as markets finish off an explosive November. In the portfolio, we adjust the size of some of our positions.

Stocks Fluctuate in Choppy Trade as Bank Shares Pull Back

Stocks Fluctuate in Choppy Trade as Bank Shares Pull Back

Stocks fluctuate on Friday afternoon in choppy trading as banks beat a retreat after days of gains.

Stocks Mixed as November Jobs Solidify Chances of December Rate Hike

Stocks Mixed as November Jobs Solidify Chances of December Rate Hike

Stocks hold mixed on Friday after U.S. jobs gains in November solidify the chances of a December rate hike.

U.S. Stocks Turn Mixed as Economy Adds 178,000 Jobs in November

U.S. Stocks Turn Mixed as Economy Adds 178,000 Jobs in November

U.S. stocks were mixed Friday, despite a better than expected jobs report.

Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab

Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab

Supported by Phase 3 Study in Patients With Non-Squamous Non-Small Cell Lung Cancer

Stock Futures Hold Lower After U.S. Adds 178,000 Jobs

Stock Futures Hold Lower After U.S. Adds 178,000 Jobs

Stock futures hold lower on Friday after U.S. job gains in November come in around forecasts.

The Most Admired Corporate Dealmakers in a Record Year

The Most Admired Corporate Dealmakers in a Record Year

In a record year for acquisitions, 18 companies from across the spectrum were singled out by M&A professionals for doing deals that got results.

Allergan Seeks to Reassure Antsy Investors but Will They Buy It?

Allergan Seeks to Reassure Antsy Investors but Will They Buy It?

Will investors want to wait 12 to 18 months to see Allergan's deals pay dividends?

Cramer: Rally Isn't Because Trump's Coming In but Because Fed's Going Out

Cramer: Rally Isn't Because Trump's Coming In but Because Fed's Going Out

Market should still be able to breathe once central-bank prop is removed.

Some 'January Effect' Stock Picks

Some 'January Effect' Stock Picks

Small-caps could also benefit from abating tax-loss selling.

Aegon To Appoint Matthew Rider As CFO

Aegon To Appoint Matthew Rider As CFO

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.

Starbucks, Facebook, Apple: Doug Kass' Views

Starbucks, Facebook, Apple: Doug Kass' Views

Doug Kass shares his thoughts on how faster growth won't be easy and how the debt and deficits are out of control.

Weekly Roundup

The markets reach record highs in a short week as oil and a potential rate hike get much of the attention.

Allergan Could Pay $1 Billion for Chase Pharma

Allergan Could Pay $1 Billion for Chase Pharma

'Milestone payments' could boost deal's $125 million announced price.

Jim Cramer's Top Takeaways: Home Depot, Corbus Pharmaceuticals

Jim Cramer's Top Takeaways: Home Depot, Corbus Pharmaceuticals

Positive results mean a lot for HD and CRBP, says Jim Cramer.